EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes

Heidi J Silver iD, Dianna Olson, Dustin Mayfield, Patricia Wright, Hui Nian, Mona Mashayekhi iD, John R Koethe, Kevin D Niswender, James M Luther, Nancy J Brown

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15113 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Heidi J Silver und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Prediabetic State, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the hypothesis that weight loss with the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) liraglutide alone would lead to a greater reduction in the proportion of fat to lean tissue mass when compared to caloric restriction (CR) alone, as well as when compared to treatment with sitagliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, that also enhances GLP‐1 activity ‐ to determine the independent effects of each treatment.

Methods

A total of 88 adults with obesity and prediabetes were randomized to 14 weeks of intervention with CR (−390 kcal/d), liraglutide (1.8 mg/d), or the dipeptidyl peptidase‐4 inhibitor sitagliptin (100 mg/d) as a weight‐neutral comparator. Changes between groups in appetite and hunger ratings measured via visual analogue scales, dietary intakes, body weight, body composition via dual energy x‐ray absorptiometry, and resting energy expenditure via indirect calorimetry were assessed using the Kruskal‐Wallis test or Pearson's chi‐squared test.

Results

Weight loss ≥5% of baseline body weight occurred in 44% of participants in the CR group, 22% of the liraglutide group and 5% of the sitagliptin group ( p = 0.02). The ratio of fat to lean mass decreased by 6.5% in the CR group, 2.2% in the liraglutide group, and 0% in the sitagliptin group ( p = 0.02). Visceral fat reduced by 9.5% in the CR group, 4.8% in the liraglutide group, and 0% in the sitagliptin group ( p = 0.04). A spontaneous reduction in dietary simple carbohydrates in the CR group was associated with improved homeostatic model assessment of insulin resistance score (HOMA‐IR).

Conclusions

Although both liraglutide and CR are valuable strategies for cardiometabolic risk reduction, CR was associated with greater weight loss and more favourable improvements in body composition than treatment with liraglutide alone. Differences in the response to each of these interventions enables patients to be stratified to the most optimal intervention for their personal risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prediabetic StateDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsCardiovascular DiseasesHumansAdultLiraglutideCaloric RestrictionAppetiteHypoglycemic AgentsSitagliptin PhosphateObesityBody WeightEatingBody Fat DistributionWeight LossDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

caloric restrictiondietglucagon-like peptide-1 (GLP-1) receptor agonistliraglutideobesityprediabetesweight loss

Substanzen

LiraglutideHypoglycemic AgentsSitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Veteran Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • School of Medicine, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Heidi J Silver, Mona Mashayekhi

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • American Heart Association
  • National Center for Advancing Translational Sciences
  • Novo Nordisk Foundation Center for Basic Metabolic Research

Zitieren

APA

Silver, H. J., Olson, D., Mayfield, D., Wright, P., Nian, H., Mashayekhi, M., Koethe, J. R., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023). Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15113

Vancouver

Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, et al. Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15113

BibTeX
@article{Silver2023,
  author = {Silver, Heidi J and Olson, Dianna and Mayfield, Dustin and Wright, Patricia and Nian, Hui and Mashayekhi, Mona and Koethe, John R and Niswender, Kevin D and Luther, James M and Brown, Nancy J},
  title = {Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15113}
}
Kostenlos starten →